Single cell resolution of human chronic kidney disease for precision medicine in nephrology

人类慢性肾病的单细胞分辨率用于肾病学精准医学

• 批准号: 433151787
• 负责人: Professor Dr. Rafael Kramann
• 金额: --
• 依托单位: Institut für Computational Biomedicine
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 2020
• 资助国家: 德国
• 起止时间: 2019-12-31 至 2021-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/433151787?language=en
• 关键词: Single; cell; resolution; human; chronic

Chronic kidney disease (CKD) affects more than 10% of the German population but lacks targeted therapies as well as precise prognostic tools. We have access to a unique biobank of human kidney biopsies with extensive clinical follow up data of up to 10 years. We are aiming to characterize 10 kidney diseases (common and rare) contributing to a majority of CKD by using single nuclear snRNA-seq and snATACseq from frozen human kidney biopsies. Living kidney donor biopsies will serve as healthy controls. We are aiming for 200 biopsies (20 per kidney disease type) with a minimum of 5 year follow up data. Among the 20 biopsies up to 10 will be included with stable kidney function during follow up and 10 with significant decline of kidney function. We will deploy new strategies for pooling patient samples and demultiplexing the data based on SNP analysis, as well as functional genomics methods tailored to single cell data to extract information about deregulated pathways, transcription factors and other processes, to identify novel biomarkers and therapeutic targets. This ambitious interdisciplinary project requires the expertise of nephrologists, computational and molecular biologists, and machine learners. It will only be possible by leveraging the resources at the DFG sequencing centers. The passion that drives this project results from a simple hypothesis: It is possible to find novel urgently needed therapeutic targets and prognostic measures for CKD using state of the art single cells genomics.

慢性肾病 (CKD) 影响着超过 10% 的德国人口，但缺乏针对性治疗以及精确的预后工具。我们可以获得独特的人类肾活检生物库，其中包含长达 10 年的广泛临床随访数据。 我们的目标是通过使用冷冻人肾活检中的单核 snRNA-seq 和 snATACseq 来表征导致大多数 CKD 的 10 种肾脏疾病（常见和罕见）。活体肾脏供体活检将作为健康对照。我们的目标是进行 200 次活检（每种肾脏疾病类型 20 次），并提供至少 5 年的随访数据。在20个活检中，最多10个在随访期间肾功能稳定，10个肾功能显着下降。我们将部署新的策略来汇集患者样本并基于 SNP 分析对数据进行多路分解，以及针对单细胞数据定制的功能基因组学方法，以提取有关解除管制的通路、转录因子和其他过程的信息，从而识别新的生物标志物和治疗靶点。这个雄心勃勃的跨学科项目需要肾脏病学家、计算和分子生物学家以及机器学习者的专业知识。这只能通过利用 DFG 测序中心的资源来实现。推动这个项目的热情源于一个简单的假设：使用最先进的单细胞基因组学有可能找到新的急需的 CKD 治疗靶点和预后措施。